维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

19篇 您的检索式：作者名="Pratz"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias显示文摘	Pratz K Cho E Levis M	2010	Leukemia2010，24，8：	1
	2	Testing the efficient market theory on the sydney wool futures exchange 显示文摘	PRATZ P D	1975	Australian Economics Papers1975，，14：	1
	3	Bench to bedside targeting of FLT3 in acute leukemia显示文摘	Pratz KW Levis MJ		0，，07：	1
	4	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML显示文摘	Pratz KW Sato T Murphy KM	2010	Blood2010，，07：	1
	5	A pharmaeodynamje study of sorafenib in patients with relapsed and refractory acute leukemills 显示文摘	Pratz KW Cho EI Evis MJ	2010	Leukemia2010，24，8：	1
	6	A pharmacodynamic study of the flt3 inhibitor kw-2449 yields insight into the basis for clinical response显示文摘	PRATZ KW CORTES J ROBOZ GJ	2009	Blood2009，113，17：	1
	7	Bench to bedside targeting of FLT3 in acute leukemia显示文摘	Pratz KW Levis MJ	2010	Curr Drug Targets2010，11，7：	1
	8	Atomic-scale magnetic domain wails in quasi-one-dimensional Fe nanostripes显示文摘	Pratze M Elmers H J Bode M	2001	Phys Rev Lett2001，87，12：	1
	9	Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients 显示文摘	VILLARROEL M C PRATZ K W XU L	2012	Invest New Drugs2012，30，6：	1
	10	AC220is a uniquely potent and selective inhibitor of FLT3 for the treatmentof acute myeloid leukemia(AML)显示文摘	Zarrinkar PP Gunawardane RN Cramer MD Gardner MF BrighamD Belli B Karaman MW Pratz KW Pallares G Chao Q	2009	Blood2009，114，：	1
	11	Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant显示文摘	Sammons SL Pratz KW Smith BD	2014	Am J Hematol2014，89，9：	1
	12	A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias显示文摘	Pratz K W Cho E Levis M J	2010	Leukemia2010，24，8：	1
	13	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML显示文摘	Pratz KW Sato T Murphy KM	2010	Blood2010，115，：	1
	14	A pharmacodynamic study of sorafenib in patients with relapsed with relapsed and refractory acute leukemias显示文摘	Pratz KW Cho E Levis MJ	2010	Leukemia2010，24，：	1
	15	FLT3- mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML显示文摘	PRATZ K W SATO T MURPHY K M	2010	Blood2010，115，：	1
	16	Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post- transplant显示文摘	Sammons S L Pratz K W Smith B D	2014	Am J Hematol2014，89，9：	1
	17	Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients显示文摘	Maria Cristina Villarroel Keith W. Pratz Linping Xu John J. Wright B. Douglas Smith Michelle A. Rudek	2012	Investigational New Drugs2012，，6：	1
	18	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML显示文摘	Pratz KW Sato T Murphy KM	2010	Blood2010，115，7：	1
	19	A pharmaeodynamie study of the FLT3 inhibitor KW-2449 yields insight into the basis for clin- ical response 显示文摘	Pratz KW Cortes J Roboz G J	2009	Blood2009，113，17：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费